Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 31


Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.

Munson EL, Du Chateau BK, Jobe DA, Lovrich SD, Callister SM, Schell RF.

Infect Immun. 2000 Oct;68(10):5496-501.


Resolution of experimental and tick-borne Borrelia burgdorferi infection in mice by passive, but not active immunization using recombinant OspC.

Zhong W, Gern L, Stehle T, Museteanu C, Kramer M, Wallich R, Simon MM.

Eur J Immunol. 1999 Mar;29(3):946-57.


Borrelia burgdorferi-infected, interleukin-6-deficient mice have decreased Th2 responses and increased lyme arthritis.

Anguita J, Rincón M, Samanta S, Barthold SW, Flavell RA, Fikrig E.

J Infect Dis. 1998 Nov;178(5):1512-5.


Borreliacidal antibody production against outer surface protein C of Borrelia burgdorferi.

Rousselle JC, Callister SM, Schell RF, Lovrich SD, Jobe DA, Marks JA, Wieneke CA.

J Infect Dis. 1998 Sep;178(3):733-41.


A vaccine consisting of recombinant Borrelia burgdorferi outer-surface protein A to prevent Lyme disease. Recombinant Outer-Surface Protein A Lyme Disease Vaccine Study Consortium.

Sigal LH, Zahradnik JM, Lavin P, Patella SJ, Bryant G, Haselby R, Hilton E, Kunkel M, Adler-Klein D, Doherty T, Evans J, Molloy PJ, Seidner AL, Sabetta JR, Simon HJ, Klempner MS, Mays J, Marks D, Malawista SE.

N Engl J Med. 1998 Jul 23;339(4):216-22. Erratum in: N Engl J Med 1998 Aug 20;339(8):571.


Vaccination against Lyme disease with recombinant Borrelia burgdorferi outer-surface lipoprotein A with adjuvant. Lyme Disease Vaccine Study Group.

Steere AC, Sikand VK, Meurice F, Parenti DL, Fikrig E, Schoen RT, Nowakowski J, Schmid CH, Laukamp S, Buscarino C, Krause DS.

N Engl J Med. 1998 Jul 23;339(4):209-15.


Protective and arthritis-resolving activity in sera of mice infected with Borrelia burgdorferi.

Barthold SW, Feng S, Bockenstedt LK, Fikrig E, Feen K.

Clin Infect Dis. 1997 Jul;25 Suppl 1:S9-17.


Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells.

Rincón M, Anguita J, Nakamura T, Fikrig E, Flavell RA.

J Exp Med. 1997 Feb 3;185(3):461-9.


Characterization of the protective borreliacidal antibody response in humans and hamsters after vaccination with a Borrelia burgdorferi outer surface protein A vaccine.

Padilla ML, Callister SM, Schell RF, Bryant GL, Jobe DA, Lovrich SD, DuChateau BK, Jensen JR.

J Infect Dis. 1996 Oct;174(4):739-46.


Sensitivity and specificity of the borreliacidal-antibody test during early Lyme disease: a "gold standard"?

Callister SM, Jobe DA, Schell RF, Pavia CS, Lovrich SD.

Clin Diagn Lab Immunol. 1996 Jul;3(4):399-402.


Borrelia burgdorferi OspA is an arthropod-specific transmission-blocking Lyme disease vaccine.

de Silva AM, Telford SR 3rd, Brunet LR, Barthold SW, Fikrig E.

J Exp Med. 1996 Jan 1;183(1):271-5.


Immunological and molecular polymorphisms of OspC, an immunodominant major outer surface protein of Borrelia burgdorferi.

Wilske B, Preac-Mursic V, Jauris S, Hofmann A, Pradel I, Soutschek E, Schwab E, Will G, Wanner G.

Infect Immun. 1993 May;61(5):2182-91.


Role of attached lipid in immunogenicity of Borrelia burgdorferi OspA.

Erdile LF, Brandt MA, Warakomski DJ, Westrack GJ, Sadziene A, Barbour AG, Mays JP.

Infect Immun. 1993 Jan;61(1):81-90.


Passive immunizing activity of sera from mice infected with Borrelia burgdorferi.

Barthold SW, Bockenstedt LK.

Infect Immun. 1993 Nov;61(11):4696-702.


Western blotting in the serodiagnosis of Lyme disease.

Dressler F, Whalen JA, Reinhardt BN, Steere AC.

J Infect Dis. 1993 Feb;167(2):392-400.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk